News | January 18, 2007

Study Aimed at Causes, Prevention of PAD

Jan. 19, 2007 — The University of Pennsylvania Health System and Life Line Screening, the nation's largest provider of mobile preventive health screenings, are collaborating to identify and recruit patients with Peripheral Arterial Disease (P.A.D.) for a pilot study on the causes and prevention of this common yet under-treated vascular disease.

"P.A.D. has a strong correlation to coronary heart disease and carries a higher risk of stroke and heart attack," says Dr. Emile R. Mohler III, director of Vascular Medicine, University of Pennsylvania Health System. "As we develop a greater understanding of how P.A.D. progresses, we'll be better equipped to help patients by determining when and how to treat them."

Using noninvasive ultrasound imaging, the research will begin to pinpoint the exact cause and progression of claudication, or outward symptoms of P.A.D., which include cramps, tiredness or pain in the legs and buttocks occurring when blood flow is restricted by atherosclerosis

For more information visit www.lifelinescreening.com.

Related Content

Annual U.S. Economic Burden of Critical Limb Ischemia Exceeds $200 Billion
News | Peripheral Artery Disease (PAD) | July 17, 2019
A new analysis published by The Sage Group LLC concludes that the all-cause cost of critical limb ischemia (CLI)...
Intact Vascular Inc. received U.S. Food and Drug Administration (FDA) market clearance for the Tack Endovascular System. This is a purpose-built dissection repair device implanted post-angioplasty in patients with peripheral arterial disease (PAD).
Technology | Peripheral Artery Disease (PAD) | April 15, 2019
April 15, 2019 – Intact Vascular Inc. received U.S.
The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

Feature | Peripheral Artery Disease (PAD) | January 30, 2019 | Dave Fornell, Editor
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...
The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

Feature | Peripheral Artery Disease (PAD) | January 25, 2019 | Dave Fornell, Editor
The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since 2003
Lumee Oxygen Platform Measures Treatment Response in Critical Limb Ischemia
News | Peripheral Artery Disease (PAD) | January 25, 2019
January 25, 2019 — Profusa announced promising...
BEST-CLI Trial Examining Critical Limb Ischemia Treatment Options Nears Enrollment Goal
News | Peripheral Artery Disease (PAD) | January 23, 2019
A new report in the Journal of Vascular Surgery chronicles a multi-site randomized controlled trial comparing treatment...
FDA Issues Letter About Paclitaxel Coated Balloons and Eluting Stents
News | Peripheral Artery Disease (PAD) | January 17, 2019
The U.S. Food and Drug Administration (FDA) issued a letter Jan. 17, 2019, to healthcare providers regarding a recent...
New Appropriate Use Criteria Released for Peripheral Artery Interventions
News | Peripheral Artery Disease (PAD) | December 19, 2018
A new set of appropriate use criteria (AUC) released Dec. 17 by a group of cardiovascular professional societies...
Lithotripsy Safe and Effective in Calcified Stenotic Peripheral Arteries
News | Peripheral Artery Disease (PAD) | December 04, 2018
New results from the DISRUPT PAD II study showed no perforations, embolization, reflow or abrupt closures with the...
Overlay Init